← Eichor
Study identifier: NCT06612645 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors

Condition: Pediatric Cancers · Solid Tumor Pediatric  ·  Sponsor: Chulalongkorn University

PhasePhase 1
Planned participants9
Who can joinAll sexes, 1 Year to 25 Years
Healthy volunteersNo

About this study

A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.

This description comes directly from the study's public registry record.

Talk to the study team

Piti Techavichit, Associate Professor, MD  ·  +66817515363  ·  Piti.T@chula.ac.th

Koramit Suppipat, MD  ·  +66816282068  ·  Koramit.S@chula.ac.th

Always discuss trial participation with your own doctor first.

Locations (1)

King Chulalongkorn Memorial HospitalBangkok, Pathumwan, ThailandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06612645